SLC29A1 and colorectal cancer: SLC29A1 (ENT1) has been implicated in the uptake of antimetabolites, and although high expression of SLC29A1 has not been reported in oral cancer, its expression level could be associated with response to 5-FU, specifically in colorectal cancer [62].